Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd-SARS-CoV-2-S (XBB.1.5)
- Development stage
- Preclinical
- Lead developer
- Washington University School of Medicine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
ChAd-SARS-CoV-2-S (XBB.1.5) is an investigational, chimpanzee adenovirus-vectored vaccine encoding a prefusion-stabilized spike (S) protein of the SARS-CoV-2 Omicron XBB.1.5 variant. Developed by researchers at Washington University School of Medicine in St. Louis, the vaccine is designed for intranasal administration to elicit robust mucosal and systemic immunity, including variant-specific IgA and IgG antibodies, as well as cross-reactive memory CD8+ T cells. By targeting the respiratory mucosa directly, the vaccine aims to prevent infection, limit viral replication in both the upper and lower respiratory tracts, and block transmission of emerging SARS-CoV-2 variants. It is currently in preclinical development.
- Other names
- ChAd-SARS-CoV-2-S against XBB.1.5 spikeChAd-SARS-CoV2-S against XBB.1.5 spikeChAd-SARS-CoV 2-S against XBB.1.5 spikeChAd-SARS-CoV-2-XBB.1.5-SChAd-SARS-CoV2-XBB.1.5-SChAd-SARS-CoV 2-XBB.1.5-S
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on ChAd-SARS-CoV-2-S (XBB.1.5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd-SARS-CoV-2-S (XBB.1.5).